Business news

Mice Model Market Size Forecasted to be Worth USD 2.00 Billion by 2027, according to a Latest Study by Emergen Research

Mice Model

The mice model market is expected to be valued at USD 2.00 billion in 2027 from USD 1.22 billion in 2019 registering a CAGR of 6.8% through the forecast period, according to a current report by Emergen Research. During the forecast period, due to the growing demand for humanised mice prototypes, the global mice model market is expected to grow significantly. The growing use of mice models in virology and infectious disease studies is expected to further propel the global demand for mice models during the forecast period. In addition, growing adoption by contract research organisations (CROs) of mice models for clinical research is expected to raise the global demand for mice models in the near future.

However, growing objections from many organizations on mouse research are expected to hinder the global mice model market to some degree during the forecast period.

Grab Your Free Sample PDF Copy Now

Key Highlights of Report

  • Charles River Laboratories International, Inc. purchased the Citoxlab Company in April 2019. This agreement would further solidify the role of Charles River as the leading, multinational, initial CRO by widening the research pipeline and geographic scope, which would improve the organization’s capacity to partner with drug discovery and development clients.
  • The inbred sub-segment is expected to lead the market during the forecast period due to the rising use of the mice model in immunology disease research and infectious disease experiments and also in monoclonal antibody manufacture.
  • The breeding sub-segment is expected to hold the largest market share and grow at a CAGR of 7.0 percent over the forecast period due to the increasing use of the mice model to produce customised drugs and also for drug growth. In addition, during the forecast period, increasing use of the mice model to identify genotypes for research purposes is projected to further fuel the segment.
  • The CRISPR sub-segment is expected to lead the market during the forecast period due to the reliability and versatility of CRISPR technology. CRISPR reduces the time needed to alter target genes so that they can be easily applied to embryos, in comparison to gene targeting methods focused on the use of embryonic stem cells.
  • The cancer sub-segment is expected to dominate the market during the forecast period. Mice models provide useful clues about a typical genome’s biological role. This is an important factor for assessing the possible validity of targeted therapy in transcriptional cancer research, as targets can be accurately inactivated in the form of a developed or growing tumour.
  • The pharmaceutical segment is expected to lead the market over the forecast period due to the rising use of the mice model for drug production and veterinary testing purposes.
  • During the forecast period, due to the presence of major market players and the increase in biomedical studies in this area, the North American region is projected to lead the global market.
  • Key market participants include Envigo Ltd, TransViragen Inc., Charles River Laboratories International Inc., GenOway S.A., The Jackson Laboratory, Ozgene Pty Ltd, GVK Biosciences Private Limited, Taconic Biosciences Inc., Pharmaron, Inc., and Horizon Discovery Group plc.

Emergen Research has segmented the global mice model market on the basis of type, service, technology, application, end-use, and region.

  • Type Outlook (Revenue, USD Billion; 2017–2027)
    • Outbred
    • Hybrid
    • Inbred
    • Knockout
    • Spontaneous Mutant
  • Service Outlook (Revenue, USD Billion; 2017–2027)
    • Cryopreservation
    • Rederivation
    • Genetic Testing
    • Breeding
    • Quarantine
    • Others
  • Technology Outlook (Revenue, USD Billion; 2017–2027)
    • CRISPR
    • Nuclear Transfer
    • Embryonic Stem Cell Injection
    • Microinjection
    • Others
  • Application Outlook (Revenue, USD Billion; 2017–2027)
    • Cancer
    • Diabetes
    • Research & Development
    • Academics
    • Cardiovascular Studies
    • Genetic Studies
    • Infectious Diseases
    • Neurological Diseases
    • Others
  • End-use Outlook (Revenue, USD Billion; 2017–2027)
    • Pharmaceutical
    • Cosmetics
    • Biotechnology
    • Government
    • Contract Research Organizations
    • Academic & Research Institutes
    • Others
  • Regional Outlook (Revenue, USD Billion; 2017–2027)
    • North America
      1. U.S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. U.K.
      3. France
      4. BENELUX
      5. Rest of Europe
    • Asia Pacific
      1. China
      2. Japan
      3. South Korea
      4. India
      5. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. Saudi Arabia
      2. U.A.E.
      3. Rest of MEA

To get leading market solutions, visit the link below:

To Top

Pin It on Pinterest

Share This